<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="chem202500747" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Chemistry</journal-id><journal-id journal-id-type="iso-abbrev">Chemistry</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1521-3765</journal-id><journal-id journal-id-type="publisher-id">CHEM</journal-id><journal-title-group><journal-title>Chemistry (Weinheim an Der Bergstrasse, Germany)</journal-title></journal-title-group><issn pub-type="ppub">0947-6539</issn><issn pub-type="epub">1521-3765</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40202773</article-id><article-id pub-id-type="pmc">PMC12099189</article-id>
<article-id pub-id-type="doi">10.1002/chem.202500747</article-id><article-id pub-id-type="publisher-id">CHEM202500747</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Osteosarcoma Cell and Osteosarcoma Stem Cell Potent Immunogenic Bi&#x02010;Nuclear Gallium(III) Complexes</article-title></title-group><contrib-group><contrib id="chem202500747-cr-0001" contrib-type="author"><name><surname>Feng</surname><given-names>Xiao</given-names></name><xref rid="chem202500747-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="chem202500747-cr-0002" contrib-type="author"><name><surname>Dhandore</surname><given-names>Shruti</given-names></name><xref rid="chem202500747-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="chem202500747-cr-0003" contrib-type="author"><name><surname>Liu</surname><given-names>Yu</given-names></name><xref rid="chem202500747-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="chem202500747-cr-0004" contrib-type="author"><name><surname>Singh</surname><given-names>Kuldip</given-names></name><xref rid="chem202500747-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="chem202500747-cr-0005" contrib-type="author" corresp="yes"><name><surname>Ortu</surname><given-names>Fabrizio</given-names></name><xref rid="chem202500747-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>fabrizio.ortu@leicester.ac.uk</email></address></contrib><contrib id="chem202500747-cr-0006" contrib-type="author" corresp="yes"><name><surname>Suntharalingam</surname><given-names>Kogularamanan</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7047-6384</contrib-id><xref rid="chem202500747-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>k.suntharalingam@leicester.ac.uk</email></address></contrib></contrib-group><aff id="chem202500747-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">School of Chemistry</named-content>
<institution>University of Leicester</institution>
<city>Leicester</city>
<postal-code>LE1 7RH</postal-code>
<country country="GB">UK</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>E&#x02010;mail: <email>k.suntharalingam@leicester.ac.uk</email>; <email>fabrizio.ortu@leicester.ac.uk</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="ppub"><day>22</day><month>5</month><year>2025</year></pub-date><volume>31</volume><issue seq="310">29</issue><issue-id pub-id-type="doi">10.1002/chem.v31.29</issue-id><elocation-id>e202500747</elocation-id><history>
<date date-type="rev-recd"><day>05</day><month>4</month><year>2025</year></date>
<date date-type="received"><day>26</day><month>2</month><year>2025</year></date>
<date date-type="accepted"><day>08</day><month>4</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 Wiley&#x02010;VCH GmbH--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). Chemistry &#x02013; A European Journal published by Wiley&#x02010;VCH GmbH</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:CHEM-31-e202500747.pdf"/><abstract><title>Abstract</title><p>We report the synthesis, characterization, anti&#x02010;osteosarcoma and anti&#x02010;osteosarcoma stem cells (OSC) properties (cytotoxic and immunogenic) of a series of bi&#x02010;nuclear gallium(III) complexes with tridentate Schiff base ligands and 8&#x02010;hydroxyquinoline (1&#x02013;4). According to monolayer cytotoxicity studies, 1&#x02013;4 display micromolar potency toward bulk osteosarcoma cells and OSCs. The most effective complex in series 2 is up to 13&#x02010;fold more potent toward OSCs than cisplatin and carboplatin (the only metallodrugs used in the clinic to treat osteosarcoma). Remarkably, the bi&#x02010;nuclear gallium(III) complexes 1&#x02013;4 are significantly more potent toward 3D&#x02010;cultured sarcospheres than OSCs cultured in monolayers indicating effective penetration of the sarcosphere multicellular architecture. The bi&#x02010;nuclear gallium(III) complexes 1&#x02013;4 are up to 53&#x02010;fold more potent toward sarcospheres than cisplatin and carboplatin. Mechanistic studies show that gallium(III) complex 2 kills osteosarcoma cells by caspase&#x02010;dependent apoptosis and paraptosis, leading to the release of danger&#x02010;associated molecular patterns associated with immunogenic cell death. Osteosarcoma cells and OSCs treated with gallium(III) complex 2 are effectively phagocytosed by immune cells, highlighting its immunogenic potential. As far as it is known, gallium(III) complex 2 is the first metal complex to evoke an immunogenic response toward both bulk osteosarcoma cells and OSCs.</p></abstract><abstract id="chem202500747-abs-0001" abstract-type="graphical"><p>Current treatment options are unable to benefit the majority of osteosarcoma patients with metastasized tumors (70&#x02013;80% 5&#x02010;year fatality rate). Osteosarcoma stem cells (OSCs), a small sub&#x02010;population of osteosarcoma cells with stem cell&#x02010;like properties, are thought to play a role in the spread of osteosarcoma. In this manuscript, we report the first metal complex to evoke an immunogenic response toward both bulk osteosarcoma cells and OSCs.
<boxed-text position="anchor" content-type="graphic"><graphic xlink:href="CHEM-31-e202500747-g005.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="chem202500747-kwd-0001">antitumor agents</kwd><kwd id="chem202500747-kwd-0002">bioinorganic chemistry</kwd><kwd id="chem202500747-kwd-0003">cancer</kwd><kwd id="chem202500747-kwd-0004">gallium</kwd><kwd id="chem202500747-kwd-0005">Schiff bases</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Engineering and Physical Sciences Research Council
</institution><institution-id institution-id-type="doi">10.13039/501100000266</institution-id></institution-wrap></funding-source><award-id>EP/W02151X/1</award-id><award-id>EP/V034766/1</award-id><award-id>EP/S005544/1</award-id><award-id>EP/W00691X/1</award-id></award-group></funding-group><counts><fig-count count="8"/><table-count count="1"/><page-count count="11"/><word-count count="6902"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 22, 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:23.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes notes-type="dedication"><p>Dedication to</p></notes></front><body><sec id="chem202500747-sec-0010"><label>1</label><title>Introduction</title><p>Osteosarcoma is the most common primary bone cancer in children and adolescents.<sup>[</sup>
<xref rid="chem202500747-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>]</sup> Osteosarcoma tends to occur in the long bones in the arms and legs and has a high tendency for metastasis.<sup>[</sup>
<xref rid="chem202500747-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>]</sup> Reportedly, 15&#x02013;20% of newly diagnosed osteosarcomas are detected with metastatic sites.<sup>[</sup>
<xref rid="chem202500747-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>
<sup>]</sup> The five&#x02010;year survival rate for osteosarcoma patients with metastasized tumors is only 20&#x02013;30%, therefore there is an urgent clinical need to develop new chemotherapeutic agents that can prevent metastasis.<sup>[</sup>
<xref rid="chem202500747-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>]</sup> Metastasis in osteosarcoma patients is heavily linked to the existence of a subpopulation of self&#x02010;renewing osteosarcoma cells called osteosarcoma stem cells (OSCs).<sup>[</sup>
<xref rid="chem202500747-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>]</sup> The current frontline chemotherapeutic regimens used to treat osteosarcoma patients (including methotrexate, cisplatin, and doxorubicin) are believed to enrich OSC populations, increasing the possibility of metastasis.<sup>[</sup>
<xref rid="chem202500747-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>]</sup> The implication of OSCs means that osteosarcoma treatments need to remove heterogeneous osteosarcoma populations in their entirety, including OSCs, otherwise OSC&#x02010;mediated metastasis could occur. Although studies have identified several OSC targets, an effective OSC&#x02010;active agent with low systematic toxicity has not been developed by academic&#x02010; or industry&#x02010;led endeavors thus far.<sup>[</sup>
<xref rid="chem202500747-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="chem202500747-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>]</sup>
</p><p>We reported the first metal&#x02010;based agents to potently kill OSCs in vitro.<sup>[</sup>
<xref rid="chem202500747-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>]</sup> Specifically, a series of gallium(III) compounds containing polypyridyl ligands were shown to kill bulk osteosarcoma cells and OSCs (in monolayer and sarcosphere cultures) within the nanomolar range.<sup>[</sup>
<xref rid="chem202500747-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>]</sup> The rationale for investigating the anti&#x02010;OSC properties of gallium(III) compounds was based on the intrinsic ability of gallium(III) salts to accumulate in bones, and the favorable safety profiles observed for gallium(III) compounds that have undergone human clinical trials (such as KP46).<sup>[</sup>
<xref rid="chem202500747-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>]</sup> The most effective gallium(III) complex in the series was over 400&#x02010;fold more potent than cisplatin toward methotrexate&#x02010;resistant OSCs, and significantly less toxic toward a panel of noncancerous cells of various tissue types (lung, breast, skin, and kidney).<sup>[</sup>
<xref rid="chem202500747-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>]</sup> Mechanistic studies showed that the lead gallium(III) complex induced apoptotic osteosarcoma cell death by entering the nucleus and damaging genomic DNA.<sup>[</sup>
<xref rid="chem202500747-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>]</sup>
</p><p>Following this work, we developed &#x0201c;second generation&#x0201d; gallium(III)&#x02010;polypyridyl complexes containing salicylic acid and diflunisal, nonsteroidal anti&#x02010;inflammatory drugs (NSAIDs), with improved anti&#x02010;OSC properties.<sup>[</sup>
<xref rid="chem202500747-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>]</sup> NSAIDs are established inhibitors of cyclooxygenase&#x02010;2 (COX&#x02010;2).<sup>[</sup>
<xref rid="chem202500747-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>]</sup> COX&#x02010;2 catalyses the formation of prostaglandin (an inflammation mediator).<sup>[</sup>
<xref rid="chem202500747-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>]</sup> COX&#x02010;2 is an established marker in osteosarcoma and its inhibition is widely thought to be a viable method of improving therapeutic outcomes.<sup>[</sup>
<xref rid="chem202500747-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>
<sup>]</sup> Histological studies have shown that COX&#x02010;2 expression in osteosarcoma patients correlates with tumor grade, metastasis potential, and lower survival rates.<sup>[</sup>
<xref rid="chem202500747-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>]</sup> COX&#x02010;2 expression is elevated in OSCs (compared to bulk osteosarcoma cells) and plays a vital role in OSC maintenance.<sup>[</sup>
<xref rid="chem202500747-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>]</sup> The diflunisal&#x02010;bearing gallium(III) complex displayed significantly higher monolayer and sarcosphere OSC potency (up to three orders of magnitude) than clinically approved osteosarcoma drugs used in frontline (doxorubicin and cisplatin) and secondary (etoposide, ifosfamide, and carboplatin) treatments.<sup>[</sup>
<xref rid="chem202500747-bib-0010" ref-type="bibr">
<sup>10a</sup>
</xref>
<sup>]</sup> Mechanistic studies showed that the diflunisal&#x02010;bearing gallium(III) complex killed osteosarcoma cells by simultaneously inhibiting COX&#x02010;2 and damaging nuclear DNA.<sup>[</sup>
<xref rid="chem202500747-bib-0010" ref-type="bibr">
<sup>10a</sup>
</xref>
<sup>]</sup> The diflunisal&#x02010;bearing gallium(III) complex was also incorporated into a clinically approved, spherical polymeric nanoparticle system (methoxy poly(ethylene glycol)&#x02010;<italic toggle="yes">b</italic>&#x02010;poly(D,L&#x02010;lactic&#x02010;co&#x02010;glycolic) acid) with the aim of improving delivery to osteosarcoma sites.<sup>[</sup>
<xref rid="chem202500747-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
<sup>]</sup> The optimized nanoparticle formulation displayed tenfold better activity toward OSCs than the payload.<sup>[</sup>
<xref rid="chem202500747-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
<sup>]</sup> The nanoparticle formulation also exhibited up to 5645&#x02010;fold greater potency toward OSCs than frontline anti&#x02010;osteosarcoma drugs, doxorubicin and cisplatin.<sup>[</sup>
<xref rid="chem202500747-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
<sup>]</sup> Furthermore, the nanoparticle formulation evoked a similar mechanism of action as the payload, which bodes well for further translation.</p><p>Immunotherapy, where the immune system is stimulated to destroy tumors, has emerged as a feasible alternative to conventional cytotoxic cancer therapies over the last decade and could provide long&#x02010;term durable therapeutic outcomes for osteosarcoma patients.<sup>[</sup>
<xref rid="chem202500747-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>
<sup>]</sup> The clinical development of osteosarcoma&#x02010;directed immunotherapy has largely focused on monoclonal antibodies and native biomolecules that can block protein&#x02010;protein interactions between T&#x02010;cell checkpoint receptors and their cognate ligands.<sup>[</sup>
<xref rid="chem202500747-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="chem202500747-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>
<sup>]</sup> Antigen&#x02010;specific immunotherapy such as adoptive T&#x02010;cell or chimeric antigen receptor (CAR)&#x02010;T&#x02010;cell therapy has also shown some promise against osteosarcoma.<sup>[</sup>
<xref rid="chem202500747-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="chem202500747-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>
<sup>]</sup> Given that osteosarcomas are considered low immunogenic tumors, the general effectiveness of current biologic approaches is somewhat limited. These biological approaches prime immune cells to seek and destroy osteosarcoma cells by recognizing protein(s) on their surface. As bulk osteosarcoma cells and OSCs express different surface protein arrays, and immunological approaches are inherently biased toward more differentiated bulk osteosarcoma cells, current biologic approaches are largely ineffective against OSCs. As far as we are aware no methods have been reported to prime immune cells to target OSCs. Mifamurtide, a synthetic analog of muramyl dipeptide, is used as an immunomodulator to treat osteosarcoma patients (and reduces the risk of dying by 13% over 5 years); however, its impact on OSCs is not reported.<sup>[</sup>
<xref rid="chem202500747-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>]</sup> In general, small molecule immuno&#x02010;chemotherapeutics offer distinct advantages over biologic approaches including; higher feasibility, opportunities for intracellular targeting, flexible formulation and dosing options to overcome pharmacokinetic and pharmacodynamics challenges, and lower costs.<sup>[</sup>
<xref rid="chem202500747-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>
<sup>]</sup> The current batch of small molecules undergoing investigation as OSC&#x02010;specific agents are typically organic and display no immunological features.<sup>[</sup>
<xref rid="chem202500747-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>
<sup>]</sup> These agents induce OSC death via cytotoxic mechanisms only, which are susceptible to acquired resistance mechanisms.</p><p>Although the potency of various gallium(III) complexes toward bulk osteosarcoma cells and OSCs has been investigated, their immunogenic potential remains unexplored.<sup>[</sup>
<xref rid="chem202500747-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="chem202500747-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>]</sup> In this study, we report the preparation, characterization, anti&#x02010;osteosarcoma and anti&#x02010;OSC properties (both cytotoxic and immunogenic) of a series of bi&#x02010;nuclear gallium(III) complexes comprising of tridentate Schiff base ligands and 8&#x02010;hydroxyquinoline. The Schiff base ligands contain two hard oxygen donor atoms to stabilize the hard gallium(III) metal centres. The use of 8&#x02010;hydroxyquinoline was inspired by the structure of KP46, a gallium(III) complex with three 8&#x02010;hydroxyquinoline units, that has progressed to human clinical trials.<sup>[</sup>
<xref rid="chem202500747-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>]</sup> Considering the inherent ability of gallium salts to amass in bones, we envisage that the bi&#x02010;nuclear gallium(III) complexes could effectively target bone material. Indeed our studies show that the bi&#x02010;nuclear gallium(III) complexes are readily absorbed onto bone material and display very promising bulk osteosarcoma cell and OSC activity in in vitro systems (both monolayer and 3D). Moreover, the most effective complex within the series displays unprecedented immunogenic potential. To the best of our knowledge, the aforementioned gallium complex reported in this study is the first metal complex to evoke an immunogenic response toward both bulk osteosarcoma cells and OSCs.</p></sec><sec id="chem202500747-sec-0020"><label>2</label><title>Results and Discussion</title><sec id="chem202500747-sec-0030"><label>2.1</label><title>Synthesis and Characterization of Bi&#x02010;Nuclear Gallium(III) Complexes</title><p>Four bi&#x02010;nuclear gallium compounds (<bold>1</bold>&#x02010;<bold>4</bold>) were prepared with various tridentate Schiff base ligands (<bold>L<sup>1</sup>
</bold>&#x02010;<bold>L<sup>4</sup>
</bold>) and 8&#x02010;hydroxyquinoline (structures depicted in Figure&#x000a0;<xref rid="chem202500747-fig-0001" ref-type="fig">1A</xref>). The Schiff base ligands (<bold>L<sup>1</sup>
</bold>&#x02010;<bold>L<sup>4</sup>
</bold>) were prepared by reacting equimolar amounts of 2&#x02010;aminophenol and the corresponding salicylaldehyde (5&#x02010;fluorosalicylaldehyde for <bold>L<sup>1</sup>
</bold>, 5&#x02010;chlorosalicylaldehyde for <bold>L<sup>2</sup>
</bold>, 5&#x02010;bromosalicylaldehyde for <bold>L<sup>3</sup>
</bold>, 5&#x02010;iodosalicylaldehyde for <bold>L<sup>4</sup>
</bold>) in methanol. The Schiff base ligands (<bold>L<sup>1</sup>
</bold>&#x02010;<bold>L<sup>4</sup>
</bold>) were isolated as yellow or orange solids in reasonable to good yields (44&#x02013;77%), and characterized by <sup>1</sup>H and <sup>19</sup>F{<sup>1</sup>H} NMR, infrared spectroscopy, and ESI mass spectrometry (see Figures&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S1&#x02013;S11</xref>, Supporting Information). Characteristic imine proton signals at 8.95&#x02013;8.98&#x000a0;ppm in the <sup>1</sup>H NMR spectra and C&#x02550;N bands at 1620&#x02013;1632&#x000a0;cm<sup>&#x02212;1</sup> in the IR spectra for <bold>L<sup>1</sup>
</bold>&#x02010;<bold>L<sup>4</sup>
</bold> confirmed formation of the imine functionality (Figures&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S1, S3&#x02013;S5</xref>, and<xref rid="chem202500747-supinfo-0001" ref-type="">S7</xref>, Supporting Information). Disappearance for the aldehyde proton peak (10.17&#x02013;10.25&#x000a0;ppm) associated to the various salicylaldehyde starting materials established full conversion to the Schiff base ligands (<bold>L<sup>1</sup>
</bold>&#x02010;<bold>L<sup>4</sup>
</bold>) (Figures&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S1</xref> and<xref rid="chem202500747-supinfo-0001" ref-type="">S3&#x02013;S6</xref>, Supporting Information). The bi&#x02010;nuclear gallium(III) complexes (<bold>1</bold>&#x02010;<bold>4</bold>) were synthesized by reacting GaCl<sub>3</sub> with equimolar amounts of <bold>L<sup>1</sup>
</bold>&#x02010;<bold>L<sup>4</sup>
</bold> and 8&#x02010;hydroxyquinoline in the presence of piperidine in ethanol. The bi&#x02010;nuclear gallium(III) complexes (<bold>1</bold>&#x02010;<bold>4</bold>) were isolated as orange solids in reasonable yields (43&#x02013;58%), and characterized by <sup>1</sup>H and <sup>19</sup>F{<sup>1</sup>H} NMR, infrared spectroscopy, ESI mass spectrometry and elemental analysis (see Figures&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S12&#x02013;S21</xref>, Supporting Information). The aromatic signals associated with the <sup>1</sup>H NMR spectra of <bold>1</bold>&#x02013;<bold>4</bold> shifted relative to <bold>L<sup>1</sup>
</bold>&#x02010;<bold>L<sup>4</sup>
</bold>, indicative of metal coordination (Figures&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S12</xref> and&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S14&#x02013;S16</xref>, Supporting Information). The fact that only one set of <sup>1</sup>H NMR signals were observed for the <bold>L<sup>1</sup>
</bold>&#x02010;<bold>L<sup>4</sup>
</bold> and 8&#x02010;hydroxyquinoline moieties in <bold>1</bold>&#x02013;<bold>4</bold> suggests that a single regioisomer was isolated in each case. The IR spectra of <bold>1</bold>&#x02013;<bold>4</bold> displayed C&#x02550;N stretching bands at relatively lower frequencies than the corresponding Schiff base ligands (<bold>L<sup>1</sup>
</bold>&#x02010;<bold>L<sup>4</sup>
</bold>), further confirming coordination of gallium to <bold>L<sup>1</sup>
</bold>&#x02010;<bold>L<sup>4</sup>
</bold> (Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S17</xref>, Supporting Information). Distinctive molecular ion peaks corresponding to <bold>1</bold>&#x02013;<bold>4</bold> with the appropriate isotopic pattern was observed in the positive mode of the high&#x02010;resolution ESI mass spectra (<italic toggle="yes">m/z</italic> = 887.0568 amu for [<bold>1</bold>+H]<sup>+</sup>; 918.9961 amu for [<bold>2</bold>+H]<sup>+</sup>; 1008.8945 amu for [<bold>3</bold>+H]<sup>+</sup>; 1102.8684 amu for [<bold>4</bold>+H]<sup>+</sup>), providing further evidence for product formation (Figures&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S18&#x02013;S21</xref>, Supporting Information). The purity of the bulk solid of <bold>1&#x02013;4</bold> was confirmed by elemental analysis (see Supporting Information).</p><fig position="float" fig-type="Figure" id="chem202500747-fig-0001"><label>Figure 1</label><caption><p>A) Chemical structure of the bi&#x02010;nuclear gallium complexes <bold>1</bold>&#x02013;<bold>4</bold> comprising of tridentate Schiff base ligands (<bold>L<sup>1</sup>
</bold>&#x02010;<bold>L<sup>4</sup>
</bold>) and 8&#x02010;hydroxyquinoline moieties. B) X&#x02010;ray structure of <bold>1</bold>. Ellipsoids are shown at 50% probability, H atoms and co&#x02010;crystalizing solvent molecules have been omitted for clarity. C in black, N in dark blue, O in red, F in green, and Ga in grey.</p></caption><graphic xlink:href="CHEM-31-e202500747-g007" position="anchor" id="jats-graphic-3"/></fig><p>Single crystals of <bold>1</bold> and <bold>2</bold> suitable for X&#x02010;ray diffraction studies were obtained by slow diffusion of diethyl ether into an acetonitrile&#x02006;solution of <bold>1</bold> and <bold>2</bold> (CCDC <ext-link xlink:href="https://www.ccdc.cam.ac.uk/services/structures?id=doi:10.1002/chem.202500747" ext-link-type="uri">2419225</ext-link>&#x02013;2419226, Table&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S1</xref>, Supporting Information; Figure&#x000a0;<xref rid="chem202500747-fig-0001" ref-type="fig">1B</xref>; Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S22</xref>, Supporting Information).<sup>[</sup>
<xref rid="chem202500747-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>
<sup>]</sup> Selected bond distance and bond angle data for <bold>1</bold> are presented in Table&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S2</xref> (Supporting Information). The data obtained for <bold>2</bold> was insufficient to reliably determine bond parameters; however, the connectivity of the bi&#x02010;nuclear gallium(III) complex could be resolved. The structures of <bold>1</bold> and <bold>2</bold> consist of two distorted octahedral gallium(III) centres, two Schiff base ligands (<bold>L<sup>1</sup>
</bold> for <bold>1</bold> and <bold>L<sup>2</sup>
</bold> for <bold>2</bold>), and two 8&#x02010;hydroxyquinoline units. As depicted in Figure&#x000a0;<xref rid="chem202500747-fig-0001" ref-type="fig">1B</xref> and Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S22</xref> (Supporting Information), each of the gallium(III) centres in <bold>1</bold> and <bold>2</bold> display different coordination environments. For <bold>1</bold>, one of the Schiff base ligands <bold>L<sup>1</sup>
</bold> (via the phenolato oxygen atom on the fluorophenyl moiety) and one of the 8&#x02010;hydroxyquinoline ligands bridge the two gallium(III) centres. For <bold>2</bold>, both of the Schiff base ligands <bold>L<sup>2</sup>
</bold> bridge the two gallium(III) centres (via different phenolato oxygen atoms on the chlorophenyl and unsubstituted phenyl moieties). The difference in ligand arrangement around the two gallium(III) centres could be partly attributed to the favorable intramolecular offset <italic toggle="yes">&#x003c0;&#x02013;&#x003c0;</italic> interaction between the fluorophenyl moieties in <bold>1</bold> (dihedral angle, &#x003a6; of 20.1(3)&#x000b0; between the least&#x02010;squares planes and a centroid&#x02010;centroid distance, <italic toggle="yes">d</italic> of 3.665(5) &#x000c5;), which is not observed for the chlorophenyl moieties in <bold>2</bold>. This is plausible as chlorophenyl moieties (compared to fluorophenyl moieties) are less polarized and thus less likely to shift the quadrupole moment of the associated phenyl ring to promote intramolecular <italic toggle="yes">&#x003c0;&#x02013;&#x003c0;</italic> interactions. The relatively short Ga&#x02010;Ga distance in <bold>1</bold> (3.1936(6) &#x000c5;) could also be partly attributed to the abovementioned intramolecular <italic toggle="yes">&#x003c0;&#x02013;&#x003c0;</italic> interactions. Overall the Ga&#x02013;O (bridging and terminal) and Ga&#x02013;N bond distances determined for <bold>1</bold> are consistent with the bond parameters for a structurally related bi&#x02010;nuclear gallium(III) complex.<sup>[</sup>
<xref rid="chem202500747-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>
<sup>]</sup> The structures of <bold>3</bold> and <bold>4</bold> are likely to be similar to those obtained for <bold>2</bold> (as depicted in Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S22</xref>, Supporting Information) based on the electronegativity and size of the bromine and iodine substituents on <bold>L<sup>3</sup>
</bold> and <bold>L<sup>4</sup>
</bold>, respectively.</p></sec><sec id="chem202500747-sec-0040"><label>2.2</label><title>Solution Stability of Bi&#x02010;Nuclear Gallium(III) Complexes</title><p>The lipophilicity of the bi&#x02010;nuclear gallium(III) complexes was determined by measuring the extent to which <bold>1</bold>&#x02013;<bold>4</bold> partitioned between octanol and water using UV&#x02013;vis spectroscopy. The experimentally determined Log P values varied from 1.51 &#x000b1;&#x000a0;0.001 to 2.10 &#x000b1;&#x000a0;0.03 (Table&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S3</xref>, Supporting Information). The nature of the substituent on the Schiff base ligands (<bold>L<sup>1</sup>
</bold>&#x02010;<bold>L<sup>4</sup>
</bold>) attached to the gallium(III) centers in <bold>1</bold>&#x02013;<bold>4</bold> influences hydrophobicity. The lipophilicity increased along with the size of the substituent, LogP value for <bold>1</bold> (F) &#x0003c;&#x000a0;<bold>2</bold> (Cl) &#x0003c;&#x000a0;<bold>3</bold> (Br) &#x0003c;&#x000a0;<bold>4</bold> (I). Overall, the LogP values for <bold>1</bold>&#x02013;<bold>4</bold> suggests that the bi&#x02010;nuclear gallium(III) complexes should be adequately soluble in aqueous media to conduct biological studies and highly cell permeable.</p><p>The solution stability of <bold>1</bold>&#x02013;<bold>4</bold> was assessed by time course UV&#x02013;vis and <sup>1</sup>H NMR spectroscopy and ESI mass spectrometry experiments. In DMSO, the UV&#x02013;vis trace associated with <bold>1</bold>&#x02013;<bold>4</bold> (50&#x000a0;&#x000b5;<sc>m</sc>) remained unchanged over the course of 24&#x000a0;h at 37 &#x000b0;C (Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S23</xref>, Supporting Information), indicative of stability. The <sup>1</sup>H NMR spectra of <bold>1</bold>&#x02013;<bold>4</bold> (10 m<sc>m</sc>) in DMSO&#x02010;<italic toggle="yes">d</italic>
<sub>6</sub> remained unaltered over the course of 72&#x000a0;h at 37 &#x000b0;C (Figures&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S24&#x02013;S27</xref>, Supporting Information), proving that <bold>1</bold>&#x02013;<bold>4</bold> do not undergo structural modifications in DMSO. The ESI mass spectra of <bold>1</bold>&#x02013;<bold>4</bold> (0.5&#x000a0;m<sc>m</sc>) in DMSO each displayed a distinctive molecular ion peak corresponding to <bold>1</bold>&#x02013;<bold>4</bold> throughout the course of 24&#x000a0;h at 37 &#x000b0;C (Figures&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S28&#x02013;S31</xref>, Supporting Information), further confirming the stability of <bold>1</bold>&#x02013;<bold>4</bold> in DMSO. The stability of <bold>1</bold>&#x02013;<bold>4</bold> in DMSO bodes well for conducting biological studies as most assays involve solubilizing the test compound in DMSO prior to dilution in the appropriate biological media. In H<sub>2</sub>O:DMSO (200:1), the UV&#x02013;vis band in 400&#x02013;450&#x000a0;nm region associated with the respective metal perturbed <italic toggle="yes">&#x003c0;&#x02013;&#x003c0;</italic>* transitions within <bold>1</bold>&#x02013;<bold>4</bold> (50&#x000a0;&#x000b5;<sc>m</sc>) decreased slightly (by 9&#x02013;16%) over the course of 24&#x000a0;h at 37 &#x000b0;C (Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S32</xref>, Supporting Information) implicative of some structural changes. To decipher the precise nature of the structural changes we attempted to grow single crystals suitable for X&#x02010;ray diffraction studies from concentrated solutions of <bold>1</bold>&#x02013;<bold>4</bold> in DMSO:H<sub>2</sub>O (1:1). Crystallization was successful for <bold>1</bold> and <bold>3</bold>. In each case the structure revealed a mono&#x02010;nuclear gallium(III) complex (<bold>1a</bold> and <bold>3a</bold>) comprising of the corresponding Schiff base ligand (<bold>L<sup>1</sup>
</bold> or <bold>L<sup>3</sup>
</bold>), 8&#x02010;hydroxyquinoline, and a DMSO molecule (bound to the gallium centre via the oxygen atom) (CCDC <ext-link xlink:href="https://www.ccdc.cam.ac.uk/services/structures?id=doi:10.1002/chem.202500747" ext-link-type="uri">2</ext-link>&#x000a0;419&#x000a0;224 and 2&#x000a0;419&#x000a0;227, Tables&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S4&#x02013;S6</xref>, Supporting Information; Figure&#x000a0;<xref rid="chem202500747-fig-0002" ref-type="fig">2A,B</xref>; Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S33</xref>, Supporting Information).<sup>[</sup>
<xref rid="chem202500747-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>
<sup>]</sup> This suggests that the bridging Ga&#x02010;O&#x02010;Ga bonds in <bold>1</bold> and <bold>3</bold> are somewhat prone to cleavage in the presence of H<sub>2</sub>O and this can lead to the formation of an adduct with DMSO. The <sup>1</sup>H NMR spectra of <bold>1</bold>&#x02013;<bold>4</bold> (10 m<sc>m</sc>) in D<sub>2</sub>O:DMSO&#x02010;<italic toggle="yes">d</italic>
<sub>6</sub> (9:1) over the course of 72&#x000a0;h at 37 &#x000b0;C was dominated by signals associated to the intact bi&#x02010;nuclear gallium(III) complexes <bold>1</bold>&#x02013;<bold>4</bold> however additional signals corresponding to the mono&#x02010;nuclear gallium(III)&#x02010;DMSO complexes <bold>1a</bold>&#x02010;<bold>4a</bold> were also observed (Figure&#x000a0;<xref rid="chem202500747-fig-0002" ref-type="fig">2C,D</xref>; Figures&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S33&#x02013;S37</xref>, Supporting Information). Collectively, the UV&#x02013;vis, XRD, and <sup>1</sup>H NMR analysis indicate that in H<sub>2</sub>O:DMSO solutions, the bi&#x02010;nuclear gallium(III) complexes <bold>1</bold>&#x02013;<bold>4</bold> are largely stable but can undergo structural transformation to form the corresponding mono&#x02010;nuclear gallium(III)&#x02010;DMSO complexes <bold>1a</bold>&#x02010;<bold>4a</bold> in small amounts. Additional time course UV&#x02013;vis spectroscopy studies in MEGM:DMSO (200:1) revealed that that the UV&#x02013;vis bands associated to <bold>1</bold>&#x02013;<bold>4</bold> (50&#x000a0;&#x000b5;<sc>m</sc>) decreased over the course of 24&#x000a0;h (Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S38</xref>, Supporting Information). The changes are similar, but more pronounced, compared to those observed in H<sub>2</sub>O:DMSO (200:1) (Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S32</xref>, Supporting Information). This implies that <bold>1</bold>&#x02013;<bold>4</bold> undergo structural changes in MEGM, and are susceptible to form the corresponding mono&#x02010;nuclear gallium(III)&#x02010;DMSO complexes <bold>1a</bold>&#x02010;<bold>4a</bold>. The observed structural changes in biologically relevant solutions could negatively impact the in vivo performance of <bold>1</bold>&#x02013;<bold>4</bold>.</p><fig position="float" fig-type="Figure" id="chem202500747-fig-0002"><label>Figure 2</label><caption><p>
<sup>1</sup>H NMR spectra of <bold>1</bold> (10 m<sc>m</sc>) in D<sub>2</sub>O:DMSO&#x02010;<italic toggle="yes">d</italic>
<sub>6</sub> (9:1) over the course of 72&#x000a0;h. A) aromatic region and B) aliphatic region. C) Chemical structure of the mono&#x02010;nuclear gallium(III) complex <bold>1a</bold> formed in DMSO:H<sub>2</sub>O (1:1). D) X&#x02010;ray structure of <bold>1a</bold>. Ellipsoids are shown at 50% probability, H atoms have been omitted for clarity. C in black, N in dark blue, O in red, S in orange, F in green, and Ga in gray.</p></caption><graphic xlink:href="CHEM-31-e202500747-g006" position="anchor" id="jats-graphic-5"/></fig></sec><sec id="chem202500747-sec-0050"><label>2.3</label><title>Bone Mineral Absorption Studies</title><p>Given the inherent ability of gallium&#x02010;containing compounds to accumulate in bones in vivo, we determined the ability of the bi&#x02010;nuclear gallium(III) complexes <bold>1</bold>&#x02013;<bold>4</bold> to be absorbed onto bone minerals using a hydroxyapatite model.<sup>[</sup>
<xref rid="chem202500747-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
<sup>]</sup> The bi&#x02010;nuclear gallium(III) complexes <bold>1</bold>&#x02013;<bold>4</bold> (0.1&#x000a0;m<sc>m</sc>) were incubated with hydroxyapatite (10 mg) in HEPES buffer at 37 &#x000b0;C and agitated (200&#x000a0;rpm). At certain time points over a 48&#x000a0;h incubation period, the amount of <bold>1</bold>&#x02013;<bold>4</bold> in solution (unbound to hydroxyapatite) was determined by ICP&#x02010;MS and used to generate depletion plots (Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S39</xref>, Supporting Information). The bi&#x02010;nuclear gallium(III) complexes <bold>1</bold> and <bold>2</bold> displayed similar absorption profiles, the amount of gallium absorbed onto hydroxyapatite steadily increased over 48&#x000a0;h, reaching a maximum of 34&#x02013;39% absorption. The bromine&#x02010; and iodine&#x02010;containing gallium(III) complexes <bold>3</bold> and <bold>4</bold> displayed rapid absorbed onto hydroxyapatite in the first 1&#x000a0;h before a relatively steady absorption profile was reached. Notably, the amount of <bold>4</bold> (71%) absorbed onto hydroxyapatite after 1&#x000a0;h incubation was significantly higher than <bold>3</bold> (42%). There was also some evidence of gallium release at longer incubation times (3&#x02013;24&#x000a0;h), suggesting that binding of <bold>3</bold> and <bold>4</bold> onto hydroxyapatite is reversible. Overall the bone mineral absorption studies indicate that the bi&#x02010;nuclear gallium(III) complexes have reasonable affinity for hydroxyapatite, with the iodine&#x02010;containing complex <bold>4</bold> displaying the greatest absorption over 48&#x000a0;h.</p></sec><sec id="chem202500747-sec-0060"><label>2.4</label><title>Cytotoxicity Toward Bulk Osteosarcoma Cells and Osteosarcoma Stem Cells</title><p>The cytotoxicity of the bi&#x02010;nuclear gallium(III) complexes <bold>1</bold>&#x02013;<bold>4</bold> toward bulk osteosarcoma cells (U2OS) and OSC&#x02010;enriched cells (U2OS&#x02010;MTX) was assessed using the MTT [3&#x02010;(4,5&#x02010;dimethylthiazol&#x02010;2&#x02010;yl)&#x02010;2,5&#x02010;diphenyltetrazolium bromide] assay. The IC<sub>50</sub> values (concentration required to reduce cell viability by 50%) were derived from dose&#x02010;response curves (Figures&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S40&#x02013;S43</xref>, Supporting Information) and are summarized in Table&#x000a0;<xref rid="chem202500747-tbl-0001" ref-type="table">1</xref>. The bi&#x02010;nuclear gallium(III) complexes <bold>1</bold>&#x02013;<bold>4</bold> displayed micromolar potency toward U2OS and U2OS&#x02010;MTX cells, with slightly higher toxicity toward bulk osteosarcoma cells than OSC&#x02010;enriched cells. The chlorine&#x02010;containing gallium(III) complex <bold>2</bold> displayed the lowest IC<sub>50</sub> values toward U2OS and U2OS&#x02010;MTX cells within the series. The chlorine&#x02010;containing complex <bold>2</bold> was fourfold and 38&#x02010;fold more potent than cisplatin and carboplatin toward U2OS cells (<italic toggle="yes">p</italic> &#x0003c;&#x000a0;0.05, <italic toggle="yes">n</italic> = 18) and fourfold and 13&#x02010;fold more potent than cisplatin and carboplatin toward U2OS&#x02010;MTX cells (<italic toggle="yes">p</italic> &#x0003c;&#x000a0;0.05, <italic toggle="yes">n</italic> = 18).<sup>[</sup>
<xref rid="chem202500747-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="chem202500747-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>]</sup> It should be noted that although <bold>2</bold> displayed similar potency toward U2OS cells as salinomycin (a cancer stem cell&#x02010;potent positive control), <bold>2</bold> was significantly less potent toward U2OS&#x02010;MTX cells than salinomycin.<sup>[</sup>
<xref rid="chem202500747-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="chem202500747-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>]</sup> Control cytotoxicity studies were conducted with the Schiff base ligands (<bold>L<sup>1</sup>
</bold>&#x02010;<bold>L<sup>4</sup>
</bold>) and Ga(NO<sub>3</sub>)<sub>3</sub>. These studies showed that <bold>L<sup>1</sup>
</bold>&#x02010;<bold>L<sup>4</sup>
</bold> were significantly less potent toward U2OS and U2OS&#x02010;MTX cells than their corresponding bi&#x02010;nuclear gallium(III) complexes <bold>1</bold>&#x02013;<bold>4</bold> (<italic toggle="yes">p</italic> &#x0003c;&#x000a0;0.05, <italic toggle="yes">n</italic> = 18, Table&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S7</xref> and Figures&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S44&#x02013;S47</xref>, Supporting Information). Ga(NO<sub>3</sub>)<sub>3</sub> was nontoxic toward U2OS and U2OS&#x02010;MTX cells (IC<sub>50</sub> value &#x0003e;&#x000a0;100&#x000a0;&#x000b5;<sc>m</sc>).<sup>[</sup>
<xref rid="chem202500747-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>]</sup> This suggests that the potency of <bold>1</bold>&#x02013;<bold>4</bold> toward bulk osteosarcoma cells and OSCs is likely to result from the intact gallium(III) bi&#x02010;nuclear complexes rather than their individual components.</p><table-wrap position="float" id="chem202500747-tbl-0001" content-type="Table"><label>Table 1</label><caption><p>IC<sub>50</sub> values of <bold>1</bold>&#x02013;<bold>4</bold>, salinomycin, cisplatin, and Ga(NO<sub>3</sub>)<sub>3</sub> against U2OS cells, U2OS&#x02010;MTX cells, and U2OS&#x02010;MTX sarcospheres.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000" valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1">Compound</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<p>U2OS</p>
<p>IC<sub>50</sub> [&#x000b5;M]<sup>[</sup>
<xref rid="chem202500747-tbl1-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
<sup>]</sup>
</p>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<p>U2OS&#x02010;MTX</p>
<p>IC<sub>50</sub> [&#x000b5;M]<sup>[</sup>
<xref rid="chem202500747-tbl1-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
<sup>]</sup>
</p>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<p>OSC&#x02010;sarcosphere</p>
<p>IC<sub>50</sub> [&#x000b5;M]<sup>[</sup>
<xref rid="chem202500747-tbl1-note-0002" ref-type="table-fn">
<sup>b</sup>
</xref>
<sup>]</sup>
</p>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="left" rowspan="1" colspan="1">5.71 &#x000b1;&#x000a0;0.04</td><td align="left" rowspan="1" colspan="1">10.74 &#x000b1;&#x000a0;0.39</td><td align="left" rowspan="1" colspan="1">0.43 &#x000b1;&#x000a0;0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>2</bold>
</td><td align="left" rowspan="1" colspan="1">4.10 &#x000b1;&#x000a0;0.19</td><td align="left" rowspan="1" colspan="1">8.70 &#x000b1;&#x000a0;0.38</td><td align="left" rowspan="1" colspan="1">0.48 &#x000b1;&#x000a0;0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>3</bold>
</td><td align="left" rowspan="1" colspan="1">5.07 &#x000b1;&#x000a0;0.21</td><td align="left" rowspan="1" colspan="1">13.71 &#x000b1;&#x000a0;0.01</td><td align="left" rowspan="1" colspan="1">0.93 &#x000b1;&#x000a0;0.13</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>4</bold>
</td><td align="left" rowspan="1" colspan="1">4.93 &#x000b1;&#x000a0;0.35</td><td align="left" rowspan="1" colspan="1">9.65 &#x000b1;&#x000a0;0.83</td><td align="left" rowspan="1" colspan="1">1.04 &#x000b1;&#x000a0;0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">Ga(NO<sub>3</sub>)<sub>3</sub>
<sup>a</sup>
</td><td align="left" rowspan="1" colspan="1">&#x0003e; 100</td><td align="left" rowspan="1" colspan="1">&#x0003e; 100</td><td align="left" rowspan="1" colspan="1">24.94 &#x000b1;&#x000a0;0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">Cisplatin<xref rid="chem202500747-tbl1-note-0001" ref-type="table-fn">
<sup>[a]</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">16.30 &#x000b1;&#x000a0;0.50</td><td align="left" rowspan="1" colspan="1">33.87 &#x000b1;&#x000a0;3.71</td><td align="left" rowspan="1" colspan="1">16.49 &#x000b1;&#x000a0;0.20</td></tr><tr><td align="left" rowspan="1" colspan="1">carboplatin<xref rid="chem202500747-tbl1-note-0001" ref-type="table-fn">
<sup>[a]</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">157.50 &#x000b1;&#x000a0;2.21</td><td align="left" rowspan="1" colspan="1">114.98 &#x000b1;&#x000a0;2.31</td><td align="left" rowspan="1" colspan="1">22.77 &#x000b1;&#x000a0;0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">salinomycin<xref rid="chem202500747-tbl1-note-0001" ref-type="table-fn">
<sup>[a]</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">6.09 &#x000b1;&#x000a0;1.06</td><td align="left" rowspan="1" colspan="1">1.49 &#x000b1;&#x000a0;0.26</td><td align="left" rowspan="1" colspan="1">4.70 &#x000b1;&#x000a0;0.08</td></tr></tbody></table><table-wrap-foot><fn id="chem202500747-tbl1-note-0001"><label>
<sup>[a]</sup>
</label><p>Determined after 72&#x000a0;h incubation (mean of three independent experiments &#x000b1; SD).</p></fn><fn id="chem202500747-tbl1-note-0002"><label>
<sup>[b]</sup>
</label><p>Determined after 10 days incubation (mean of three independent experiments &#x000b1; SD).</p></fn><fn id="chem202500747-tbl1-note-0003"><label>
<sup>[c]</sup>
</label><p>Reported in references<sup>[</sup>
<xref rid="chem202500747-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>]</sup> and<sup>[</sup>
<xref rid="chem202500747-bib-0010" ref-type="bibr">
<sup>10a</sup>
</xref>
<sup>]</sup>.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="chem202500747-sec-0070"><label>2.5</label><title>Activity Toward Sarcospheres</title><p>Given the promising potency of the bi&#x02010;nuclear gallium(III) complexes <bold>1</bold>&#x02013;<bold>4</bold> toward osteosarcoma cells cultured in monolayers, their activity toward 3D&#x02010;cultured sarcospheres (also called osteospheres) was determined. When U2OS&#x02010;MTX cells are cultured in low&#x02010;attachment, serum&#x02010;free conditions, sarcospheres are formed. Sarcospheres are irregularly shaped collections of OSCs that are reasonable physical mimics of osteosarcomas in vivo. Incubation of single cell suspensions of U2OS&#x02010;MTX cells with <bold>1</bold>&#x02013;<bold>4</bold> (at their corresponding IC<sub>20</sub> value for 10 days) markedly reduced the formation of sarcospheres compared to untreated control cells (Figure&#x000a0;<xref rid="chem202500747-fig-0003" ref-type="fig">3</xref>). Cisplatin (IC<sub>20</sub> value, 10 days) only slightly reduced the formation of sarcospheres compared to untreated control cells (Figure&#x000a0;<xref rid="chem202500747-fig-0003" ref-type="fig">3</xref>), whereas salinomycin (IC<sub>20</sub> value, 10 days) disrupted the formation of sarcospheres to a similar extent as <bold>1</bold>&#x02013;<bold>4</bold> (Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S48</xref>, Supporting Information). The colorimetric resazurin&#x02010;based reagent, TOX8 was used to determine the effect of <bold>1</bold>&#x02013;<bold>4</bold> on sarcosphere viability. Dose&#x02010;response curves indicated that <bold>1</bold>&#x02013;<bold>4</bold> displayed low micromolar or sub&#x02010;micromolar potency toward sarcospheres (Table&#x000a0;<xref rid="chem202500747-tbl-0001" ref-type="table">1</xref>; Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S49</xref>, Supporting Information). According to the IC<sub>50</sub> values obtained from the cell and sarcosphere viability studies (Table&#x000a0;<xref rid="chem202500747-tbl-0001" ref-type="table">1</xref>), <bold>1</bold>&#x02013;<bold>4</bold> were significantly more potent toward 3D&#x02010;cultured sarcospheres than U2OS&#x02010;MTX cells grown in monolayer cultures (up to 25&#x02010;fold). This is highly atypical as most anticancer drug candidates tend to be more potent toward cells grown in monolayer systems than the same cells cultured as spheroids. This result implies that <bold>1</bold>&#x02013;<bold>4</bold> are able to effectively penetrate the multicellular architecture of sarcospheres, which is an attractive feature with respect to in vivo translation. Notably, <bold>1</bold>&#x02013;<bold>4</bold> exhibited significantly higher potency toward sarcospheres than cisplatin (up to 38&#x02010;fold, <italic toggle="yes">p</italic> &#x0003c;&#x000a0;0.05), carboplatin (up to 53&#x02010;fold, <italic toggle="yes">p</italic> &#x0003c;&#x000a0;0.05), salinomycin (up to 11&#x02010;fold, <italic toggle="yes">p</italic> &#x0003c;&#x000a0;0.05), and Ga(NO<sub>3</sub>)<sub>3</sub> (up to 58&#x02010;fold, <italic toggle="yes">p</italic> &#x0003c;&#x000a0;0.05).<sup>[</sup>
<xref rid="chem202500747-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="chem202500747-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>]</sup>
</p><fig position="float" fig-type="Figure" id="chem202500747-fig-0003"><label>Figure 3</label><caption><p>Representative bright&#x02010;field images (&#x000d7; 10) of U2OS&#x02010;MTX sarcospheres in the absence and presence of <bold>1</bold>&#x02013;<bold>4</bold> or cisplatin at their respective IC<sub>20</sub> values for 10 days.</p></caption><graphic xlink:href="CHEM-31-e202500747-g008" position="anchor" id="jats-graphic-7"/></fig></sec><sec id="chem202500747-sec-0080"><label>2.6</label><title>Cellular Uptake Studies</title><p>To provide insight into the mechanism of action of the bi&#x02010;nuclear gallium(III) complexes, cellular uptake studies were carried out. U2OS cells were incubated with <bold>1</bold>&#x02013;<bold>4</bold> (5 &#x000b5;<sc>m</sc> for 24&#x000a0;h) and the internalized gallium content was determined by inductively coupled plasma mass spectrometry (ICP&#x02010;MS) (Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S50</xref>, Supporting Information). The bi&#x02010;nuclear gallium(III) complexes <bold>1</bold>&#x02013;<bold>4</bold> were readily taken up by U2OS cells, with whole cell uptake ranging from 56.46 &#x000b1;&#x000a0;1.60 ppb of Ga/ million cells for <bold>3</bold> to 73.77 &#x000b1;&#x000a0;2.34 ppb of Ga/ million cells for <bold>4</bold>. Fractionation studies were conducted with <bold>2</bold> as a representative member of the series (Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S51</xref>, Supporting Information). A large proportion of internalized <bold>2</bold> was detected in the cytoplasm (70%) suggesting that <bold>2</bold>&#x02010;mediated osteosarcoma cell toxicity is likely to be related to interactions with cytoplasmic biomolecules. Nevertheless, a relatively small but appreciable amount of internalized <bold>2</bold> was also detected in the nucleus (4%) indicating that a genomic DNA damage related mechanism of action for <bold>2</bold> could not be completely ruled out.</p></sec><sec id="chem202500747-sec-0090"><label>2.7</label><title>Mode of Cell Death</title><p>To shed light on the mode of osteosarcoma cell death induced by <bold>2</bold>, cytotoxicity studies were performed in the presence of inhibitors for distinct cell death pathways (Figure&#x000a0;<xref rid="chem202500747-fig-0004" ref-type="fig">4A</xref>; Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S52</xref> and Table&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S8</xref>, Supporting Information). Specifically, apoptosis (z&#x02010;VAD&#x02010;FMK, 5&#x000a0;&#x000b5;<sc>m</sc>),<sup>[</sup>
<xref rid="chem202500747-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>
<sup>]</sup> necroptosis (necrostatin&#x02010;1, 20&#x000a0;&#x000b5;<sc>m</sc>),<sup>[</sup>
<xref rid="chem202500747-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>
<sup>]</sup> ferroptosis (ferrostatin&#x02010;1, 10&#x000a0;&#x000b5;<sc>m</sc>),<sup>[</sup>
<xref rid="chem202500747-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
<sup>]</sup> autophagy (chloroquine, 10&#x000a0;&#x000b5;<sc>m</sc>),<sup>[</sup>
<xref rid="chem202500747-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>
<sup>]</sup> and paraptosis (cycloheximide, 1&#x000a0;&#x000b5;<sc>m</sc>)<sup>[</sup>
<xref rid="chem202500747-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>
<sup>]</sup> inhibitors were used. The IC<sub>50</sub> value of <bold>2</bold> toward U2OS cells did not change significantly when co&#x02010;incubated with necrostatin&#x02010;1, ferrostatin&#x02010;1 or chloroquine implying that <bold>2</bold> is unlikely to induce osteosarcoma cell death by necroptosis, ferroptosis or autophagy. The IC<sub>50</sub> value of <bold>2</bold> toward U2OS cells increased significantly (<italic toggle="yes">p</italic> &#x0003c;&#x000a0;0.05, <italic toggle="yes">n</italic> = 18) in the presence of z&#x02010;VAD&#x02010;FMK and cycloheximide indicating that <bold>2</bold> is likely to induce apoptosis and paraptosis in osteosarcoma cells.</p><fig position="float" fig-type="Figure" id="chem202500747-fig-0004"><label>Figure 4</label><caption><p>A) Representative dose&#x02010;response curves for the treatment of U2OS cells with <bold>2</bold> in the absence and presence of z&#x02010;VAD&#x02010;FMK (5 &#x000b5;<sc>m</sc>) or cycloheximide (1 &#x000b5;<sc>m</sc>) after 72&#x000a0;h incubation. B) FITC Annexin V&#x02010;propidium iodide binding assay plots of untreated U2OS cells and U2OS cells treated with <bold>2</bold> (2 &#x000d7; IC<sub>50</sub> for 72&#x000a0;h) or <bold>2</bold> (4 &#x000d7; IC<sub>50</sub> for 72&#x000a0;h) or cisplatin (50&#x000a0;&#x000b5;<sc>m</sc> for 72&#x000a0;h). C) Immunoblotting analysis of proteins involved in the apoptosis cell death pathway. Protein expression in U2OS cells following treatment with <bold>2</bold> (2.1&#x02013;8.2&#x000a0;&#x000b5;<sc>m</sc>) for 72&#x000a0;h.</p></caption><graphic xlink:href="CHEM-31-e202500747-g002" position="anchor" id="jats-graphic-9"/></fig><p>Apoptosis can result in the reorganization of the cell membrane, whereby phosphatidylserine residues are translocated from the interior to the exterior.<sup>[</sup>
<xref rid="chem202500747-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>
<sup>]</sup> The exposure of phosphatidylserine residues on the cell membrane exterior can be detected by Annexin V.<sup>[</sup>
<xref rid="chem202500747-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>
<sup>]</sup> Apoptosis can also result in widespread cell membrane damage, which enables cell impermeable agents such as propidium iodide to penetrate the cell membrane.<sup>[</sup>
<xref rid="chem202500747-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>
<sup>]</sup> The dual FITC Annexin V&#x02010;propidium iodide staining flow cytometry assay was used to determine if <bold>2</bold> induced morphological changes to osteosarcoma cells were consistent with apoptosis (Figure&#x000a0;<xref rid="chem202500747-fig-0004" ref-type="fig">4B</xref>). Incubation of U2OS cells with <bold>2</bold> (2 &#x000d7; IC<sub>50</sub> value or 4 &#x000d7; IC<sub>50</sub> value for 72&#x000a0;h) led to a significant increase in the population of cells expressing late&#x02010;stage apoptotic&#x02010;like features (Figure&#x000a0;<xref rid="chem202500747-fig-0004" ref-type="fig">4B</xref>). A marked increase in the population of cells displaying late&#x02010;stage apoptotic features was also observed upon treatment with cisplatin (50&#x000a0;&#x000b5;<sc>m</sc> for 72&#x000a0;h), an established apoptosis inducer (Figure&#x000a0;<xref rid="chem202500747-fig-0004" ref-type="fig">4B</xref>). Independent immunoblotting studies showed that U2OS cells treated with <bold>2</bold> (2.1&#x02013;8.2&#x000a0;&#x000b5;<sc>m</sc> for 72&#x000a0;h) displayed higher levels of cleaved caspase 3 and 7, and poly&#x02010;ADP ribose polymerase (PARP) compared to untreated U2OS cells (Figure&#x000a0;<xref rid="chem202500747-fig-0004" ref-type="fig">4C</xref>), indicative of caspase&#x02010;dependent apoptosis.</p><p>The morphology of osteosarcoma cells treated with <bold>2</bold> was investigated using an inverted microscope. Upon incubation of U2OS cells with <bold>2</bold> (4 &#x000d7; IC<sub>50</sub> value for 24&#x000a0;h), a clear increase in intracellular vacuolization was observed (Figure&#x000a0;<xref rid="chem202500747-fig-0005" ref-type="fig">5A</xref>). Intracellular vacuolization was significantly attenuated when <bold>2</bold> (4 &#x000d7; IC<sub>50</sub> value for 24&#x000a0;h) was co&#x02010;treated with cycloheximide (1 &#x000b5;<sc>m</sc>) but not chloroquine (10 &#x000b5;<sc>m</sc>) (Figure&#x000a0;<xref rid="chem202500747-fig-0005" ref-type="fig">5A</xref>). Given that cycloheximide is a protein synthesis inhibitor that halts paraptosis<sup>[</sup>
<xref rid="chem202500747-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="chem202500747-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>
<sup>]</sup> and chloroquine inhibits autophagic flux and blocks autophagosome fusion,<sup>[</sup>
<xref rid="chem202500747-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>
<sup>]</sup> the morphology studies suggest that <bold>2</bold>&#x02010;induced vacuole formation could be a manifestation of paraptosis and not autophagy.<sup>[</sup>
<xref rid="chem202500747-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>
<sup>]</sup> The inhibition of proteasomal activity and the subsequent accumulation of ubiquitinated proteins is a distinctive feature associated to paraptosis.<sup>[</sup>
<xref rid="chem202500747-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>
<sup>]</sup> Independent immunoblotting studies showed that U2OS cells treated with <bold>2</bold> (2.1&#x02013;8.2&#x000a0;&#x000b5;<sc>m</sc> for 72&#x000a0;h) displayed noticeably higher levels of poly&#x02010;ubiquitinated proteins than untreated U2OS cells (Figure&#x000a0;<xref rid="chem202500747-fig-0005" ref-type="fig">5B</xref>), implicative of paraptosis. AIP&#x02010;1/Alix is a phylogenetically conserved cytosolic scaffold protein that inhibits paraptosis.<sup>[</sup>
<xref rid="chem202500747-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>
<sup>]</sup> Immunoblotting studies indicated a noticeable decrease in AIP&#x02010;1/Alix expression in U2OS cells treated with <bold>2</bold> (4.1&#x02013;16.4&#x000a0;&#x000b5;<sc>m</sc> for 4&#x000a0;h) (Figure&#x000a0;<xref rid="chem202500747-fig-0005" ref-type="fig">5B</xref>), providing further evidence of <bold>2</bold>&#x02010;induced paraptosis. During paraptosis, perturbations in intracellular calcium transport are common.<sup>[</sup>
<xref rid="chem202500747-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>
<sup>]</sup> Paraptosis&#x02010;inducing agents trigger calcium release from the ER to the cytoplasm.<sup>[</sup>
<xref rid="chem202500747-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>
<sup>]</sup> Relative cytoplasmic calcium levels were monitored using the calcium&#x02010;specific Fluo&#x02010;4 AM dye. U2OS cells treated with <bold>2 (</bold>2 &#x000d7; IC<sub>50</sub> value) for 24&#x000a0;h displayed a significant increase (46%) in cytoplasmic calcium levels compared to untreated cells (Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S53</xref>, Supporting Information). The elevation in <bold>2</bold>&#x02010;induced cytoplasmic calcium levels was significantly attenuated (<italic toggle="yes">p</italic> &#x0003c;&#x000a0;0.05, 36% reduction) in the presence of cycloheximide (1 &#x000b5;<sc>m</sc>) (Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S53</xref>, Supporting Information), suggesting that the perturbation in calcium homeostasis induced <bold>2</bold> is related to its ability to evoke paraptosis. A common downstream characteristic for paraptosis&#x02010;inducing agents is the increase in intracellular reactive oxygen species (ROS) levels.<sup>[</sup>
<xref rid="chem202500747-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>
<sup>]</sup> Perturbations in intracellular ROS levels upon incubation of U2OS cells with <bold>2</bold> (2 &#x000d7; IC<sub>50</sub> value or 4 &#x000d7; IC<sub>50</sub> value) were measured using the well&#x02010;established ROS detector, 6&#x02010;carboxy&#x02010;2&#x02032;,7&#x02032;&#x02010;dichlorodihydrofluorescein diacetate (DCFH&#x02010;DA), over the course of 24&#x000a0;h (Figure&#x000a0;<xref rid="chem202500747-fig-0005" ref-type="fig">5C</xref>). U2OS cells treated with <bold>2</bold> displayed a significant (<italic toggle="yes">p</italic> &#x0003c;&#x000a0;0.05) increase in intracellular ROS levels, at short (0.5&#x000a0;h) and prolonged (16&#x02013;24&#x000a0;h) incubation times (up to 3.8&#x02010;fold). This suggests that <bold>2</bold> has the potential to induce ROS&#x02010;mediated paraptosis. Overall, the mechanistic investigations suggest that <bold>2</bold> can induce hallmarks of both apoptosis and paraptosis in osteosarcoma cells.</p><fig position="float" fig-type="Figure" id="chem202500747-fig-0005"><label>Figure 5</label><caption><p>A) Representative bright&#x02010;field images (&#x000d7; 60) of untreated U2OS cells, U2OS cells treated with <bold>2</bold> (4 &#x000d7; IC<sub>50</sub> value for 24&#x000a0;h), U2OS cells co&#x02010;treated with <bold>2</bold> (4 &#x000d7; IC<sub>50</sub> value for 24&#x000a0;h) and cycloheximide (1 &#x000b5;<sc>m</sc> for 24&#x000a0;h), and U2OS cells co&#x02010;treated with <bold>2</bold> (4 &#x000d7; IC<sub>50</sub> value for 24&#x000a0;h) and chloroquine (10 &#x000b5;<sc>m</sc> for 24&#x000a0;h). B) Immunoblotting analysis of proteins related to the paraptosis pathway. Protein expression in U2OS cells following treatment with <bold>2</bold> (2.1&#x02013;8.2&#x000a0;&#x000b5;<sc>m</sc> after 72&#x000a0;h incubation or 4.1&#x02013;16.4&#x000a0;&#x000b5;<sc>m</sc> after 4&#x000a0;h incubation). C) Normalized ROS activity in untreated U2OS cells and U2OS cells treated with <bold>2</bold> (2 &#x000d7; IC<sub>50</sub> value or 4 &#x000d7; IC<sub>50</sub> value for 0.5, 1, 3, 6, 16, and 24&#x000a0;h). Error bars represent standard deviations.</p></caption><graphic xlink:href="CHEM-31-e202500747-g004" position="anchor" id="jats-graphic-11"/></fig></sec><sec id="chem202500747-sec-0100"><label>2.8</label><title>Immunogenic Cell Death and Phagocytosis</title><p>Both apoptosis and paraptosis can result in the release or exposure of danger&#x02010;associated molecular patterns (DAMPs), ATP, calreticulin, and high&#x02010;mobility group box 1, which are biomarkers of immunogenic cell death (ICD).<sup>[</sup>
<xref rid="chem202500747-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="chem202500747-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>
<sup>]</sup> Given that <bold>2</bold> is able to evoke apoptosis and paraptosis of osteosarcoma cells, we investigated whether it could also induce DAMP release or exposure. U2OS cells treated with <bold>2</bold> (2 &#x000d7; IC<sub>50</sub> value or 4 &#x000d7; IC<sub>50</sub> value for 24&#x000a0;h) displayed markedly higher levels of CRT on their cell membrane than untreated control cells (Figure&#x000a0;<xref rid="chem202500747-fig-0006" ref-type="fig">6A</xref>). U2OS cells treated with cisplatin (150 &#x000b5;<sc>m</sc> for 24&#x000a0;h) and thapsigargin (7 &#x000b5;<sc>m</sc> for 24&#x000a0;h), a combination known to induce ICD,<sup>[</sup>
<xref rid="chem202500747-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>
<sup>]</sup> also displayed a clear increase in CRT on their cell membrane (Figure&#x000a0;<xref rid="chem202500747-fig-0006" ref-type="fig">6B</xref>). A luciferase&#x02010;based assay was used to determine the release of ATP from U2OS cells treated with <bold>2</bold>. U2OS cells treated with <bold>2</bold> (2 &#x000d7; IC<sub>50</sub> value or 4 &#x000d7; IC<sub>50</sub> value for 24&#x000a0;h) released ATP in a dose&#x02010;dependent manner (up to 2.2&#x02010;fold more than untreated cells) (Figure&#x000a0;<xref rid="chem202500747-fig-0006" ref-type="fig">6C</xref>). As expected, cisplatin (50&#x000a0;&#x000b5;<sc>m</sc> for 24&#x000a0;h) also induced significant ATP release (1.7&#x02010;fold more than untreated cells) (Figure&#x000a0;<xref rid="chem202500747-fig-0006" ref-type="fig">6C</xref>). Immunoblotting studies showed that U2OS cells treated with <bold>2</bold> (2.1&#x02013;8.2&#x000a0;&#x000b5;<sc>m</sc> for 72&#x000a0;h) displayed markedly lower or undetectable amounts of HMGB&#x02010;1 relative to untreated control cells, indicative of HMGB&#x02010;1 expulsion (Figure&#x000a0;<xref rid="chem202500747-fig-0006" ref-type="fig">6D</xref>). Overall, the DAMP detection studies suggest that <bold>2</bold> is capable of inducing ICD of osteosarcoma.</p><fig position="float" fig-type="Figure" id="chem202500747-fig-0006"><label>Figure 6</label><caption><p>A,B) Representative histograms displaying the green fluorescence emitted by anti&#x02010;CRT Alexa Fluor 488&#x000a0;nm antibody&#x02010;stained U2OS cells (A) untreated (blue), and treated with <bold>2</bold> (2 &#x000d7; IC<sub>50</sub> value) (green) or <bold>2</bold> (4 &#x000d7; IC<sub>50</sub> value) (red) for 24&#x000a0;h and (B) U2OS cells untreated (blue) and treated with cisplatin (150 &#x000b5;<sc>m</sc>) and thapsigargin (7 &#x000b5;<sc>m</sc>) (green) for 24&#x000a0;h. C) Normalized extracellular ATP released from U2OS cells untreated and treated with <bold>2</bold> (2 &#x000d7; IC<sub>50</sub> value and 4 &#x000d7; IC<sub>50</sub> value) or cisplatin (50&#x000a0;&#x000b5;<sc>m</sc>) for 24&#x000a0;h. D) Immunoblotting analysis of high mobility group box 1 (HMGB&#x02010;1). Protein expression in U2OS cells following treatment with <bold>2</bold> (2.1&#x02013;8.2&#x000a0;&#x000b5;<sc>m</sc>) for 72&#x000a0;h.</p></caption><graphic xlink:href="CHEM-31-e202500747-g001" position="anchor" id="jats-graphic-13"/></fig><p>After ICD, dead cancer cells need to be phagocytosed and processed before a targeted immune response can be activated. The ability of U2OS and U2OS&#x02010;MTX cells treated with <bold>2</bold> to be phagocytosed by macrophages was determined using an in vitro phagocytosis assay. U2OS or U2OS&#x02010;MTX cells pre&#x02010;stained with CellTracker Green were treated with <bold>2</bold> (25&#x02013;50 &#x000b5;<sc>m</sc> for 24&#x000a0;h) and then incubated with macrophages pre&#x02010;stained with CellTracker Orange for 2&#x000a0;h. The population of double&#x02010;stained macrophages and engulfed U2OS or U2OS&#x02010;MTX cells is indicated in the 2D scatter plots shown in Figure&#x000a0;<xref rid="chem202500747-fig-0007" ref-type="fig">7</xref> and Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S54</xref> (Supporting Information). The phagocytosis assay showed that <bold>2</bold> (25&#x02013;50 &#x000b5;<sc>m</sc> for 24&#x000a0;h) was able to significantly enhance engulfment of U2OS and U2OS&#x02010;MTX cells by macrophages (up to 98&#x02010;fold increase compared to untreated U2OS cells, Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S54</xref>, Supporting Information and up to 18&#x02010;fold increase compared to untreated U2OS&#x02010;MTX cells, Figure&#x000a0;<xref rid="chem202500747-fig-0007" ref-type="fig">7</xref>). The addition of cisplatin (150 &#x000b5;<sc>m</sc> for 24&#x000a0;h) and thapsigargin (7 &#x000b5;<sc>m</sc> for 24&#x000a0;h) to U2OS or U2OS&#x02010;MTX cells also resulted in a significant increase in the population of double&#x02010;stained macrophages (3&#x02013;24&#x02010;fold increase compared to untreated cells, Figure&#x000a0;<xref rid="chem202500747-fig-0007" ref-type="fig">7</xref>; Figure&#x000a0;<xref rid="chem202500747-supinfo-0001" ref-type="">S54</xref>, Supporting Information) indicative of phagocytosis. Overall, these results show that bi&#x02010;nuclear gallium(III) complex <bold>2</bold> is able to kill osteosarcoma cells and OSCs in a manner that promotes engulfment by macrophages.</p><fig position="float" fig-type="Figure" id="chem202500747-fig-0007"><label>Figure 7</label><caption><p>A&#x02013;D) Representative 2D scatter plots of CellTracker Green&#x02010;stained U2OS&#x02010;MTX cells (A) untreated and treated with (B) cisplatin (150 &#x000b5;<sc>m</sc>) and thapsigargin (7 &#x000b5;<sc>m</sc>) or (C) <bold>2</bold> (25&#x000a0;&#x000b5;<sc>m</sc>) or (D) <bold>2</bold> (50&#x000a0;&#x000b5;<sc>m</sc>) for 24&#x000a0;h and then co&#x02010;cultured with CellTracker Orange&#x02010;stained THP&#x02010;1 macrophages for 2&#x000a0;h.</p></caption><graphic xlink:href="CHEM-31-e202500747-g003" position="anchor" id="jats-graphic-15"/></fig></sec></sec><sec id="chem202500747-sec-0110"><label>3</label><title>Conclusion</title><p>In summary, we report the synthesis, characterization, anti&#x02010;osteosarcoma and anti&#x02010;OSC activity of a series of bi&#x02010;nuclear gallium(III) complexes <bold>1</bold>&#x02013;<bold>4</bold> containing two tridentate Schiff base ligands (with various halogen substituents) and two 8&#x02010;hydroxyquinoline moieties. X&#x02010;ray crystallography studies revealed that the structure of the bi&#x02010;nuclear gallium(III) complexes <bold>1</bold> and <bold>2</bold> comprise of two distorted octahedral gallium(III) centres with the Schiff base ligands and 8&#x02010;hydroxyquinoline occupying both terminal and bridging positions. The bi&#x02010;nuclear gallium(III) complexes <bold>1</bold>&#x02013;<bold>4</bold> displayed micromolar potency toward bulk osteosarcoma and OSCs cultured in monolayer systems. The most active bi&#x02010;nuclear gallium(III) complex <bold>2</bold> was up to fourfold and 13&#x02010;fold more potent toward OSCs than cisplatin and carboplatin, respectively. The bi&#x02010;nuclear gallium(III) complexes <bold>1</bold>&#x02013;<bold>4</bold> were able to reduce the viability of sarcospheres (cultured in 3D conditions) in the low micromolar or sub&#x02010;micromolar range. Based on the IC<sub>50</sub> values, <bold>1</bold>&#x02013;<bold>4</bold> were up to 25&#x02010;fold more potent toward sarcospheres than monolayer cultured OSCs. This is atypical for small molecule anticancer agents (as they tend to display the opposite trend) and suggests that <bold>1</bold>&#x02013;<bold>4</bold> have the capacity to penetrate the multicellular nature of sarcospheres. This is also a highly attractive feature with respect to translation. Remarkably, <bold>1</bold>&#x02013;<bold>4</bold> were up to 53&#x02010;fold more active toward sarcospheres than cisplatin, carboplatin, and salinomycin. Detailed mechanistic studies indicated that osteosarcoma cells killed by the most active bi&#x02010;nuclear gallium(III) complex <bold>2</bold> displayed both apoptosis and paraptosis characteristics. Specifically, osteosarcoma cells treated with <bold>2</bold> displayed phosphatidylserine residues on their cell membrane exterior and an increase in cleaved caspase 3 and 7 and PARP&#x02010;1 levels, implicative of caspase&#x02010;dependent apoptosis. Osteosarcoma cells treated with <bold>2</bold> also exhibited specific hallmarks associated with paraptosis such as intracellular vacuolizsation, an increase in ubiquitinated proteins, a decrease in AIP&#x02010;1/Alix expression, and significant increases in intracellular calcium and ROS levels. Osteosarcoma cells dosed with <bold>2</bold> exhibited DAMPs consistent with ICD, such as CRT exposure on their cell membrane exterior and extracellular release of ATP and HMGB&#x02010;1. Phagocytosis studies showed that osteosarcoma cells and OSCs dosed with <bold>2</bold> were effectively engulfed by macrophages, highlighting the promising immunogenic potential of <bold>2</bold>. To the best of our knowledge, <bold>2</bold> is the first metal complex to display both cytotoxic and immunogenic effects toward bulk osteosarcoma cells and OSCs. Not only does this study reinforce the therapeutic potential of gallium(III) complexes but it also provides the basis for the development of other metal complexes as anti&#x02010;osteosarcoma drug candidates. Furthermore, the results show that metal complexes that can induce paraptosis can be effective immunotherapeutic agents toward chemotherpy resistant osteosarcoma sub&#x02010;populations such as OSCs.</p></sec><sec id="chem202500747-sec-0120"><title>Supporting Information</title><p>The authors have cited additional references within the Supporting Information.<sup>[</sup>
<xref rid="chem202500747-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>
<sup>]</sup>
</p></sec><sec sec-type="COI-statement" id="chem202500747-sec-0140"><title>Conflict of Interests</title><p>The authors declare no conflict of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="chem202500747-supinfo-0001" position="float" content-type="local-data"/><supplementary-material id="chem202500747-supitem-0001" position="float" content-type="local-data"><caption><p>Supporting Information</p></caption><media xlink:href="CHEM-31-e202500747-s001.pdf"/></supplementary-material></sec></body><back><ack id="chem202500747-sec-0130"><title>Acknowledgements</title><p>K.S. and F.O. are supported by Engineering and Physical Sciences Research Council (EPSRC) New Investigator Awards (EP/S005544/1 and EP/W00691X/1). X.F. is supported by a Chinese Scholarship Council PhD studentship. The Advanced Imaging Facility (RRID:SCR_020967) at the University of Leicester is also thanked. XRD crystallography at the University of Leicester is supported by an EPSRC Core Equipment Award (EP/V034766/1). NMR Spectroscopy at the University of Leicester is supported by an EPSRC Strategic Equipment Award (EP/W02151X/1).</p></ack><sec sec-type="data-availability" id="chem202500747-sec-0160"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list id="chem202500747-bibl-0001"><ref id="chem202500747-bib-0001"><label>1</label><mixed-citation publication-type="book" id="chem202500747-cite-0001">a) <string-name>
<given-names>A. K.</given-names>
<surname>Raymond</surname>
</string-name>, <source>World Health Organization classification of tumours : pathology and genetics Tumours of Soft Tissue and Bone</source>
<year>2002</year>, <fpage>264</fpage>;</mixed-citation><mixed-citation publication-type="journal" id="chem202500747-cite-0002">b) <string-name>
<given-names>V. Y.</given-names>
<surname>Jo</surname>
</string-name>, <string-name>
<given-names>C. D. M.</given-names>
<surname>Fletcher</surname>
</string-name>, <source>Pathology</source>
<year>2014</year>, <volume>46</volume>, <fpage>95</fpage>.<pub-id pub-id-type="pmid">24378391</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="chem202500747-cite-0003">a) <string-name>
<given-names>A.</given-names>
<surname>Luetke</surname>
</string-name>, <string-name>
<given-names>P. A.</given-names>
<surname>Meyers</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Lewis</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Juergens</surname>
</string-name>, <source>Cancer Treat. Rev.</source>
<year>2014</year>, <volume>40</volume>, <fpage>523</fpage>;<pub-id pub-id-type="pmid">24345772</pub-id>
</mixed-citation><mixed-citation publication-type="journal" id="chem202500747-cite-0004">b) <string-name>
<given-names>G.</given-names>
<surname>Sheng</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Gao</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Wu</surname>
</string-name>, <source>Front. Oncol.</source>
<year>2021</year>, <volume>11</volume>, <elocation-id>780264</elocation-id>.<pub-id pub-id-type="pmid">34956899</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="chem202500747-cite-0005">
<string-name>
<given-names>G.</given-names>
<surname>Bacci</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Rocca</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Salone</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Balladelli</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Ferrari</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Palmerini</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Forni</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Briccoli</surname>
</string-name>, <source>J. Surg. Oncol.</source>
<year>2008</year>, <volume>98</volume>, <fpage>415</fpage>.<pub-id pub-id-type="pmid">18792969</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0004"><label>4</label><mixed-citation publication-type="miscellaneous" id="chem202500747-cite-0006">a) <article-title>American Cancer Society, Survival Rates for Osteosarcoma</article-title>, (accessed Feburary <bold>2025</bold>) <ext-link xlink:href="http://www.cancer.org/cancer/bone-cancer/detection-diagnosis-staging/survival-statistics" ext-link-type="uri">www.cancer.org/cancer/bone&#x02010;cancer/detection&#x02010;diagnosis&#x02010;staging/survival&#x02010;statistics</ext-link>;</mixed-citation><mixed-citation publication-type="journal" id="chem202500747-cite-0007">b) <string-name>
<given-names>L.</given-names>
<surname>Mirabello</surname>
</string-name>, <string-name>
<given-names>R. J.</given-names>
<surname>Troisi</surname>
</string-name>, <string-name>
<given-names>S. A.</given-names>
<surname>Savage</surname>
</string-name>, <source>Int. J. Cancer</source>
<year>2009</year>, <volume>125</volume>, <fpage>229</fpage>.<pub-id pub-id-type="pmid">19330840</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="chem202500747-cite-0008">a) <string-name>
<given-names>G. N.</given-names>
<surname>Yan</surname>
</string-name>, <string-name>
<given-names>Y. F.</given-names>
<surname>Lv</surname>
</string-name>, <string-name>
<given-names>Q. N.</given-names>
<surname>Guo</surname>
</string-name>, <source>Cancer Lett.</source>
<year>2016</year>, <volume>370</volume>, <fpage>268</fpage>;<pub-id pub-id-type="pmid">26571463</pub-id>
</mixed-citation><mixed-citation publication-type="journal" id="chem202500747-cite-0009">b) <string-name>
<given-names>H. K.</given-names>
<surname>Brown</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Tellez&#x02010;Gabriel</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Heymann</surname>
</string-name>, <source>Cancer Lett.</source>
<year>2017</year>, <volume>386</volume>, <fpage>189</fpage>;<pub-id pub-id-type="pmid">27894960</pub-id>
</mixed-citation><mixed-citation publication-type="journal" id="chem202500747-cite-0010">c) <string-name>
<given-names>V. A.</given-names>
<surname>Siclari</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Qin</surname>
</string-name>, <source>J. Orthop. Surg. Res.</source>
<year>2010</year>, <volume>5</volume>, <fpage>78</fpage>.<pub-id pub-id-type="pmid">20979639</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="chem202500747-cite-0011">a) <string-name>
<given-names>S. R.</given-names>
<surname>Martins&#x02010;Neves</surname>
</string-name>, <string-name>
<given-names>D. I.</given-names>
<surname>Paiva&#x02010;Oliveira</surname>
</string-name>, <string-name>
<given-names>P. M.</given-names>
<surname>Wijers&#x02010;Koster</surname>
</string-name>, <string-name>
<given-names>A. J.</given-names>
<surname>Abrunhosa</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Fontes&#x02010;Ribeiro</surname>
</string-name>, <string-name>
<given-names>J. V.</given-names>
<surname>Bovee</surname>
</string-name>, <string-name>
<given-names>A. M.</given-names>
<surname>Cleton&#x02010;Jansen</surname>
</string-name>, <string-name>
<given-names>C. M.</given-names>
<surname>Gomes</surname>
</string-name>, <source>Cancer Lett.</source>
<year>2016</year>, <volume>370</volume>, <fpage>286</fpage>;<pub-id pub-id-type="pmid">26577806</pub-id>
</mixed-citation><mixed-citation publication-type="journal" id="chem202500747-cite-0012">b) <string-name>
<given-names>Q. L.</given-names>
<surname>Tang</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Liang</surname>
</string-name>, <string-name>
<given-names>X. B.</given-names>
<surname>Xie</surname>
</string-name>, <string-name>
<given-names>J. Q.</given-names>
<surname>Yin</surname>
</string-name>, <string-name>
<given-names>C. Y.</given-names>
<surname>Zou</surname>
</string-name>, <string-name>
<given-names>Z. Q.</given-names>
<surname>Zhao</surname>
</string-name>, <string-name>
<given-names>J. N.</given-names>
<surname>Shen</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Wang</surname>
</string-name>, <source>Chin. J. Cancer</source>
<year>2011</year>, <volume>30</volume>, <fpage>426</fpage>.<pub-id pub-id-type="pmid">21627865</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="chem202500747-cite-0013">
<string-name>
<given-names>B.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Ma</surname>
</string-name>, <string-name>
<given-names>R. K.</given-names>
<surname>Jha</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Gurung</surname>
</string-name>, <source>Acta Oncol.</source>
<year>2011</year>, <volume>50</volume>, <fpage>1142</fpage>.<pub-id pub-id-type="pmid">21718210</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="chem202500747-cite-0014">
<string-name>
<given-names>P.</given-names>
<surname>Robin</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Singh</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Suntharalingam</surname>
</string-name>, <source>Chem. Commun.</source>
<year>2020</year>, <volume>56</volume>, <fpage>1509</fpage>.</mixed-citation></ref><ref id="chem202500747-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="chem202500747-cite-0015">
<string-name>
<given-names>C. R.</given-names>
<surname>Chitambar</surname>
</string-name>, <source>Future Med. Chem.</source>
<year>2012</year>, <volume>4</volume>, <fpage>1257</fpage>.<pub-id pub-id-type="pmid">22800370</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="chem202500747-cite-0016">a) <string-name>
<given-names>Z.</given-names>
<surname>Xiao</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Passeri</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Northcote&#x02010;Smith</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Singh</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Suntharalingam</surname>
</string-name>, <source>Chem.&#x02010;Eur. J.</source>
<year>2021</year>, <volume>27</volume>, <elocation-id>13846</elocation-id>;<pub-id pub-id-type="pmid">34269487</pub-id>
</mixed-citation><mixed-citation publication-type="journal" id="chem202500747-cite-0017">b) <string-name>
<given-names>R. A.</given-names>
<surname>Vincent</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Passeri</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Northcote&#x02010;Smith</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Singh</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Suntharalingam</surname>
</string-name>, <source>ChemBioChem</source>
<year>2022</year>, <volume>23</volume>, <elocation-id>e202200532</elocation-id>.<pub-id pub-id-type="pmid">36281941</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="chem202500747-cite-0018">
<string-name>
<given-names>S. B.</given-names>
<surname>Abramson</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Weissmann</surname>
</string-name>, <source>Arthritis Rheum.</source>
<year>1989</year>, <volume>32</volume>, <fpage>1</fpage>.<pub-id pub-id-type="pmid">2643434</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="chem202500747-cite-0019">
<string-name>
<given-names>C. A.</given-names>
<surname>Rouzer</surname>
</string-name>, <string-name>
<given-names>L. J.</given-names>
<surname>Marnett</surname>
</string-name>, <source>J. Lipid Res.</source>
<year>2009</year>, <volume>50</volume>, <fpage>S29</fpage>.<pub-id pub-id-type="pmid">18952571</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="chem202500747-cite-0020">a) <string-name>
<given-names>D. P.</given-names>
<surname>Duan</surname>
</string-name>, <string-name>
<given-names>X. Q.</given-names>
<surname>Dang</surname>
</string-name>, <string-name>
<given-names>K. Z.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>Y. P.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>W. L.</given-names>
<surname>You</surname>
</string-name>, <source>Oncol. Rep.</source>
<year>2012</year>, <volume>28</volume>, <fpage>1693</fpage>;<pub-id pub-id-type="pmid">22922684</pub-id>
</mixed-citation><mixed-citation publication-type="journal" id="chem202500747-cite-0021">b) <string-name>
<given-names>Z. H.</given-names>
<surname>El&#x02010;Badawi</surname>
</string-name>, <string-name>
<given-names>E. M.</given-names>
<surname>Muhammad</surname>
</string-name>, <string-name>
<given-names>H. H.</given-names>
<surname>Noaman</surname>
</string-name>, <source>Malays. J. Pathol.</source>
<year>2012</year>, <volume>34</volume>, <fpage>15</fpage>.<pub-id pub-id-type="pmid">22870593</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="chem202500747-cite-0022">
<string-name>
<given-names>H.</given-names>
<surname>Urakawa</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Nishida</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Naruse</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Nakashima</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Ishiguro</surname>
</string-name>, <source>Clin. Orthop. Relat. Res.</source>
<year>2009</year>, <volume>467</volume>, <fpage>2932</fpage>.<pub-id pub-id-type="pmid">19326179</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="chem202500747-cite-0023">
<string-name>
<given-names>L. Y.</given-names>
<surname>Pang</surname>
</string-name>, <string-name>
<given-names>E. L.</given-names>
<surname>Gatenby</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Kamida</surname>
</string-name>, <string-name>
<given-names>B. A.</given-names>
<surname>Whitelaw</surname>
</string-name>, <string-name>
<given-names>T. R.</given-names>
<surname>Hupp</surname>
</string-name>, <string-name>
<given-names>D. J.</given-names>
<surname>Argyle</surname>
</string-name>, <source>PLoS One</source>
<year>2014</year>, <volume>9</volume>, <elocation-id>e83144</elocation-id>.<pub-id pub-id-type="pmid">24416158</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="chem202500747-cite-0024">
<string-name>
<given-names>G.</given-names>
<surname>Passeri</surname>
</string-name>, <string-name>
<given-names>R. A.</given-names>
<surname>Vincent</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Xiao</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Northcote&#x02010;Smith</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Suntharalingam</surname>
</string-name>, <source>ChemMedChem</source>
<year>2023</year>, <volume>18</volume>, <elocation-id>e202200599</elocation-id>.<pub-id pub-id-type="pmid">36533570</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="chem202500747-cite-0025">
<string-name>
<given-names>S.</given-names>
<surname>Yu</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Yao</surname>
</string-name>, <source>Mol. Cancer</source>
<year>2024</year>, <volume>23</volume>, <fpage>192</fpage>.<pub-id pub-id-type="pmid">39245737</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="chem202500747-cite-0026">
<string-name>
<given-names>C.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Xie</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Ren</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Huang</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Guo</surname>
</string-name>, <source>Cancer Lett</source>
<year>2021</year>, <volume>500</volume>, <fpage>1</fpage>.<pub-id pub-id-type="pmid">33359211</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="chem202500747-cite-0027">
<string-name>
<given-names>P. M.</given-names>
<surname>Anderson</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Tomaras</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>McConnell</surname>
</string-name>, <source>Drugs Today</source>
<year>2010</year>, <volume>46</volume>, <fpage>327</fpage>.</mixed-citation></ref><ref id="chem202500747-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="chem202500747-cite-0028">
<string-name>
<given-names>J. L.</given-names>
<surname>Adams</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Smothers</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Srinivasan</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Hoos</surname>
</string-name>, <source>Nat. Rev. Drug Discovery</source>
<year>2015</year>, <volume>14</volume>, <fpage>603</fpage>.<pub-id pub-id-type="pmid">26228631</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="chem202500747-cite-0029">a) <string-name>
<given-names>Q. L.</given-names>
<surname>Tang</surname>
</string-name>, <string-name>
<given-names>Z. Q.</given-names>
<surname>Zhao</surname>
</string-name>, <string-name>
<given-names>J. C.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Liang</surname>
</string-name>, <string-name>
<given-names>J. Q.</given-names>
<surname>Yin</surname>
</string-name>, <string-name>
<given-names>C. Y.</given-names>
<surname>Zou</surname>
</string-name>, <string-name>
<given-names>X. B.</given-names>
<surname>Xie</surname>
</string-name>, <string-name>
<given-names>Y. X.</given-names>
<surname>Zeng</surname>
</string-name>, <string-name>
<given-names>J. N.</given-names>
<surname>Shen</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Kang</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Wang</surname>
</string-name>, <source>Cancer Lett.</source>
<year>2011</year>, <volume>311</volume>, <fpage>113</fpage>;<pub-id pub-id-type="pmid">21835542</pub-id>
</mixed-citation><mixed-citation publication-type="journal" id="chem202500747-cite-0030">b) <string-name>
<given-names>L.</given-names>
<surname>Peng</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Jiang</surname>
</string-name>, <source>PLoS One</source>
<year>2018</year>, <volume>13</volume>, <elocation-id>e0205918</elocation-id>;<pub-id pub-id-type="pmid">30356255</pub-id>
</mixed-citation><mixed-citation publication-type="journal" id="chem202500747-cite-0031">c) <string-name>
<given-names>W.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Zhao</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Su</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Jia</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Shen</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Yin</surname>
</string-name>, <source>Cell Death Dis.</source>
<year>2018</year>, <volume>9</volume>, <fpage>343</fpage>.<pub-id pub-id-type="pmid">29497056</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0022"><label>22</label><mixed-citation publication-type="miscellaneous" id="chem202500747-cite-0032">
<article-title>2419225 (for <bold>1</bold>), 2419224 (for <bold>1a</bold>), 2419226 (for <bold>2</bold>), and 2419227 (for <bold>3a</bold>) contain(s) the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe</article-title>, <ext-link xlink:href="http://www.ccdc.cam.ac.uk/structures" ext-link-type="uri">http://www.ccdc.cam.ac.uk/structures</ext-link> Access Structures service</mixed-citation></ref><ref id="chem202500747-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="chem202500747-cite-0033">
<string-name>
<given-names>J.</given-names>
<surname>Qiao</surname>
</string-name>, <string-name>
<given-names>L. D.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Duan</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>D. Q.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Qiu</surname>
</string-name>, <source>Inorg. Chem.</source>
<year>2004</year>, <volume>43</volume>, <fpage>5096</fpage>.<pub-id pub-id-type="pmid">15285686</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="chem202500747-cite-0034">
<string-name>
<given-names>D. M.</given-names>
<surname>Weekes</surname>
</string-name>, <string-name>
<given-names>C. F.</given-names>
<surname>Ramogida</surname>
</string-name>, <string-name>
<given-names>M. d. G.</given-names>
<surname>Jaraquemada&#x02010;Pel&#x000e1;ez</surname>
</string-name>, <string-name>
<given-names>B. O.</given-names>
<surname>Patrick</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Apte</surname>
</string-name>, <string-name>
<given-names>T. I.</given-names>
<surname>Kostelnik</surname>
</string-name>, <string-name>
<given-names>J. F.</given-names>
<surname>Cawthray</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Murphy</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Orvig</surname>
</string-name>, <source>Inorg. Chem.</source>
<year>2016</year>, <volume>55</volume>, <elocation-id>12544</elocation-id>.<pub-id pub-id-type="pmid">27989179</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="chem202500747-cite-0035">
<string-name>
<given-names>M.</given-names>
<surname>Garcia&#x02010;Calvo</surname>
</string-name>, <string-name>
<given-names>E. P.</given-names>
<surname>Peterson</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Leiting</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Ruel</surname>
</string-name>, <string-name>
<given-names>D. W.</given-names>
<surname>Nicholson</surname>
</string-name>, <string-name>
<given-names>N. A.</given-names>
<surname>Thornberry</surname>
</string-name>, <source>J. Biol. Chem.</source>
<year>1998</year>, <volume>273</volume>, <elocation-id>32608</elocation-id>.<pub-id pub-id-type="pmid">9829999</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="chem202500747-cite-0036">
<string-name>
<given-names>A.</given-names>
<surname>Degterev</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Huang</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Boyce</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Jagtap</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Mizushima</surname>
</string-name>, <string-name>
<given-names>G. D.</given-names>
<surname>Cuny</surname>
</string-name>, <string-name>
<given-names>T. J.</given-names>
<surname>Mitchison</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Moskowitz</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Yuan</surname>
</string-name>, <source>Nat. Chem. Biol.</source>
<year>2005</year>, <volume>1</volume>, <fpage>112</fpage>.<pub-id pub-id-type="pmid">16408008</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="chem202500747-cite-0037">
<string-name>
<given-names>S. J.</given-names>
<surname>Dixon</surname>
</string-name>, <string-name>
<given-names>K. M.</given-names>
<surname>Lemberg</surname>
</string-name>, <string-name>
<given-names>M. R.</given-names>
<surname>Lamprecht</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Skouta</surname>
</string-name>, <string-name>
<given-names>E. M.</given-names>
<surname>Zaitsev</surname>
</string-name>, <string-name>
<given-names>C. E.</given-names>
<surname>Gleason</surname>
</string-name>, <string-name>
<given-names>D. N.</given-names>
<surname>Patel</surname>
</string-name>, <string-name>
<given-names>A. J.</given-names>
<surname>Bauer</surname>
</string-name>, <string-name>
<given-names>A. M.</given-names>
<surname>Cantley</surname>
</string-name>, <string-name>
<given-names>W. S.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Morrison</surname>
</string-name>, 3rd, <string-name>
<given-names>B. R.</given-names>
<surname>Stockwell</surname>
</string-name>, <source>Cell</source>
<year>2012</year>, <volume>149</volume>, <fpage>1060</fpage>.<pub-id pub-id-type="pmid">22632970</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="chem202500747-cite-0038">
<string-name>
<given-names>T.</given-names>
<surname>Shintani</surname>
</string-name>, <string-name>
<given-names>D. J.</given-names>
<surname>Klionsky</surname>
</string-name>, <source>Science</source>
<year>2004</year>, <volume>306</volume>, <fpage>990</fpage>.<pub-id pub-id-type="pmid">15528435</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="chem202500747-cite-0039">
<string-name>
<given-names>Y.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Wen</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Hao</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Jiang</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>He</surname>
</string-name>, <source>Biomed. Pharmacother.</source>
<year>2019</year>, <volume>118</volume>, <elocation-id>109203</elocation-id>.<pub-id pub-id-type="pmid">31306970</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="chem202500747-cite-0040">
<string-name>
<given-names>P. J.</given-names>
<surname>Quinn</surname>
</string-name>, <source>Subcell. Biochem.</source>
<year>2002</year>, <volume>36</volume>, <fpage>39</fpage>.<pub-id pub-id-type="pmid">12037989</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="chem202500747-cite-0041">
<string-name>
<given-names>I.</given-names>
<surname>Vermes</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Haanen</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Steffens&#x02010;Nakken</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Reutelingsperger</surname>
</string-name>, <source>J. Immunol. Methods</source>
<year>1995</year>, <volume>184</volume>, <fpage>39</fpage>.<pub-id pub-id-type="pmid">7622868</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="chem202500747-cite-0042">
<string-name>
<given-names>T.</given-names>
<surname>Schneider&#x02010;Poetsch</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Ju</surname>
</string-name>, <string-name>
<given-names>D. E.</given-names>
<surname>Eyler</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Dang</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Bhat</surname>
</string-name>, <string-name>
<given-names>W. C.</given-names>
<surname>Merrick</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Green</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Shen</surname>
</string-name>, <string-name>
<given-names>J. O.</given-names>
<surname>Liu</surname>
</string-name>, <source>Nat. Chem. Biol.</source>
<year>2010</year>, <volume>6</volume>, <fpage>209</fpage>.<pub-id pub-id-type="pmid">20118940</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="chem202500747-cite-0043">
<string-name>
<given-names>S.</given-names>
<surname>Hanson</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Dharan</surname>
</string-name>, <string-name>
<given-names>J. P.</given-names>
<surname>V&#x02009;</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Pal</surname>
</string-name>, <string-name>
<given-names>B. G.</given-names>
<surname>Nair</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Kar</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Mishra</surname>
</string-name>, <source>Front. Pharmacol.</source>
<year>2023</year>, <volume>14</volume>, <elocation-id>1159409</elocation-id>. <ext-link xlink:href="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1159409/full" ext-link-type="uri">https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1159409/full</ext-link>.<pub-id pub-id-type="pmid">37397502</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="chem202500747-cite-0044">
<string-name>
<given-names>S.</given-names>
<surname>Sperandio</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Poksay</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>de Belle</surname>
</string-name>, <string-name>
<given-names>M. J.</given-names>
<surname>Lafuente</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Nasir</surname>
</string-name>, <string-name>
<given-names>D. E.</given-names>
<surname>Bredesen</surname>
</string-name>, <source>Cell Death Differ.</source>
<year>2004</year>, <volume>11</volume>, <fpage>1066</fpage>.<pub-id pub-id-type="pmid">15195070</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="chem202500747-cite-0045">
<string-name>
<given-names>E.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>D. M.</given-names>
<surname>Lee</surname>
</string-name>, <string-name>
<given-names>M. J.</given-names>
<surname>Seo</surname>
</string-name>, <string-name>
<given-names>H. J.</given-names>
<surname>Lee</surname>
</string-name>, <string-name>
<given-names>K. S.</given-names>
<surname>Choi</surname>
</string-name>, <source>Front. Cell Devt. Biol.</source>
<year>2020</year>, <volume>8</volume>, <elocation-id>607844</elocation-id>.</mixed-citation></ref><ref id="chem202500747-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="chem202500747-cite-0046">
<string-name>
<given-names>C.&#x02010;C.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>Y.&#x02010;F.</given-names>
<surname>Lin</surname>
</string-name>, <string-name>
<given-names>M.&#x02010;Y.</given-names>
<surname>Huang</surname>
</string-name>, <string-name>
<given-names>X.&#x02010;I.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>M.&#x02010;Q.</given-names>
<surname>Huang</surname>
</string-name>, <string-name>
<given-names>J.&#x02010;J.</given-names>
<surname>Lu</surname>
</string-name>, <source>Acta Pharmacol. Sin.</source>
<year>2024</year>, <volume>45</volume>, <fpage>223</fpage>.<pub-id pub-id-type="pmid">37715003</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="chem202500747-cite-0047">a) <string-name>
<given-names>G.</given-names>
<surname>Kroemer</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Galluzzi</surname>
</string-name>, <string-name>
<given-names>O.</given-names>
<surname>Kepp</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Zitvogel</surname>
</string-name>, <source>Annu. Rev. Immunol.</source>
<year>2013</year>, <volume>31</volume>, <fpage>51</fpage>;<pub-id pub-id-type="pmid">23157435</pub-id>
</mixed-citation><mixed-citation publication-type="journal" id="chem202500747-cite-0048">b) <string-name>
<given-names>D. V.</given-names>
<surname>Krysko</surname>
</string-name>, <string-name>
<given-names>A. D.</given-names>
<surname>Garg</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Kaczmarek</surname>
</string-name>, <string-name>
<given-names>O.</given-names>
<surname>Krysko</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Agostinis</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Vandenabeele</surname>
</string-name>, <source>Nat. Rev. Cancer</source>
<year>2012</year>, <volume>12</volume>, <fpage>860</fpage>.<pub-id pub-id-type="pmid">23151605</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="chem202500747-cite-0049">
<string-name>
<given-names>I.</given-names>
<surname>Martins</surname>
</string-name>, <string-name>
<given-names>O.</given-names>
<surname>Kepp</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Schlemmer</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Adjemian</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Tailler</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Shen</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Michaud</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Menger</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Gdoura</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Tajeddine</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Tesniere</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Zitvogel</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Kroemer</surname>
</string-name>, <source>Oncogene</source>
<year>2011</year>, <volume>30</volume>, <fpage>1147</fpage>.<pub-id pub-id-type="pmid">21151176</pub-id>
</mixed-citation></ref><ref id="chem202500747-bib-0039"><label>39</label><mixed-citation publication-type="book" id="chem202500747-cite-0050">a) <string-name>
<given-names>G. M.</given-names>
<surname>Sheldrick</surname>
</string-name>, in <source>Program for Area Detector Absorption Correction</source>, <publisher-name>Institute for Inorganic Chemistry, University of G&#x000f6;ttingen: G&#x000f6;ttingen</publisher-name>, <publisher-loc>Germany</publisher-loc>
<year>1996</year>;</mixed-citation><mixed-citation publication-type="journal" id="chem202500747-cite-0051">b) <string-name>
<given-names>G. M.</given-names>
<surname>Sheldrick</surname>
</string-name>, <source>Acta Crystallogr. Sect. A: Found. Crystallogr.</source>
<year>2008</year>, <volume>64</volume>, <fpage>112</fpage>;</mixed-citation><mixed-citation publication-type="journal" id="chem202500747-cite-0052">c) <string-name>
<given-names>G. M.</given-names>
<surname>Sheldrick</surname>
</string-name>, <source>Acta Crystallogr. Sect. C</source>
<year>2015</year>, <volume>71</volume>, <fpage>3</fpage>;</mixed-citation><mixed-citation publication-type="journal" id="chem202500747-cite-0053">d) <string-name>
<given-names>O. V.</given-names>
<surname>Dolomanov</surname>
</string-name>, <string-name>
<given-names>L. J.</given-names>
<surname>Bourhis</surname>
</string-name>, <string-name>
<given-names>R. J.</given-names>
<surname>Gildea</surname>
</string-name>, <string-name>
<given-names>J. A. K.</given-names>
<surname>Howard</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Puschmann</surname>
</string-name>, <source>J. Appl. Crystallogr.</source>
<year>2009</year>, <volume>42</volume>, <fpage>339</fpage>.</mixed-citation></ref></ref-list></back></article>